A Potent (R)-alpha-bis-lipoyl Derivative Containing 8-Hydroxyquinoline Scaffold: Synthesis and Biological Evaluation of Its Neuroprotective Capabilities in SH-SY5Y Human Neuroblastoma Cells

Ivana Cacciatore 1,*, Erika Fornasari 1, Leonardo Baldassarre 1, Catia Cornacchia 1, Stefania Fulle 2,3, Ester Sara Di Filippo 2,3, Tiziana Pietrangelo 2,3 and Francesco Pinnen 1

1 Dipartimento di Farmacia, Università degli Studi “G. D’Annunzio”, Via dei Vestini 31, 66100 Chieti, Italy
2 Dipartimento di Neuroscienze e Imaging; IIM - Istituto Interuniversitario di Miologia Università degli Studi “G. D’Annunzio”, Via dei Vestini 31, 66100 Chieti, Italy
3 Ce.SI. Centro Studi Invecchiamento, Fondazione d’Annunzio, Via Colle dell’Ara, 66100 Chieti, Italy

* Author to whom correspondence should be addressed; E-Mail: cacciatore@unich.it; Tel.: +39-871-355-4475; Fax: +39-871-355-4470.

Received: 6 December 2012; in revised form: 18 December 2012 / Accepted: 31 December 2012 / Published: 7 January 2013

Abstract: A novel bis-lipoyl derivative containing 8-hydroxyquinoline scaffold (LA-HQ-LA, 5) was synthesized as a new multifunctional drug candidate with antioxidant, chelant, and neuroprotective properties for the treatment of neurodegenerative diseases. We have investigated the potential effectiveness of LA-HQ-LA against the cytotoxicity induced by 6-OHDA and H2O2 on human neuroblastoma SH-SY5Y cell line. Our outcomes showed that LA-HQ-LA resulted in significant neuroprotective and antioxidant effects against H2O2- and 6-OHDA-induced neurotoxicity in human neuroblastoma SH-SY5Y cells, as assessed by MTT assay. In particular, it showed potent neuroprotective effects against 6-OHDA in RA/PMA differentiated cells at all the tested concentrations.

Keywords: (R)-alpha-lipoic acid; 8-hydroxyquinoline; neuroprotective agent; antioxidants; neurodegenerative diseases
1. Introduction

Neurodegenerative diseases comprise a condition in which nerve cells from brain and spinal cord are lost leading to either functional loss (ataxia) or sensory dysfunction (dementia). Mitochondrial dysfunctions, excitotoxicity, and, finally, apoptosis have been reported as pathological causes for aging and neurodegenerative diseases such as Parkinson’s disease (PD), Alzheimer’s disease (AD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS) [1]. Although any disease mentioned above is characterized by its own molecular mechanism and clinical onset, common pathways can be identified as: 1) oxidative stress and free radicals formation; 2) metal dyshomeostasis; 3) protein misfolding and aggregation; and 4) mitochondrial dysfunctions [2]. Oxidative stress plays a key role in neurodegenerative diseases: it arises due to an imbalance between pro-oxidant/antioxidant homeostasis that further takes part in generation of ROS and free radicals potentially toxic for neuronal cells [3]. Furthermore, in all forms of ROS generation molecular oxygen needs to be activated by a range of metallo-enzymes, thus facilitating ROS generation upon interaction of redox metals with O$_2$ using various catalytic pathways. Since free radicals are toxic to cells, under normal circumstances, cells have an efficient regulating system for O$_2$ and metal ion interaction leading to free radicals and ROS generation [4]. In fact, during the Fenton reaction, hydroxyl radicals are produced from hydrogen peroxide in the presence of a metal in a low oxidation state:

$$\text{H}_2\text{O}_2 + \text{M}^{n+} \rightarrow \text{HO}^- + \text{HO}^+ + \text{M}^{(n+1)^+}$$

Fenton chemistry may occur in neurons of the nervous tissue where levels of both hydrogen peroxide and cerebral biometals—such as Fe$^{3+}$; Cu$^{2+}$; and Zn$^{2+}$—are found. Several studies have indicated that cerebral biometal dyshomeostasis and oxidative stress are intimately associated [5]. An in vitro AD model has shown that both A$\beta$-40 and A$\beta$-42 deposits are formed after incubation of immobilized $\beta$-amyloid oligomers with Cu$^{2+}$, Zn$^{2+}$, or Fe$^{3+}$. In these conditions, Fe$^{3+}$ promoted the deposition of fibrillar amyloid plaques, while Cu$^{2+}$ and Zn$^{2+}$ only induced the formation of amorphous aggregates [5]. In an in vitro PD model, it has been found that Fe$^{3+}$ enhanced intracellular aggregation of $\alpha$-synuclein and led to the formation of advanced glycation end products. The accumulation of these factors strongly contributed to the progression of the neurodegenerative process [6].

Increasingly medicinal chemistry approaches are currently under study to discover new drugs able to remove excess of specific metals [7,8] and to prevent or block the oxidative process that characterizes PD and AD [9–12]. Taking into account that drugs with two or more useful biological activities for the same pathology may represent an important pharmacological advance, we are currently interested in multifunctional drugs that combine potent antioxidant, chelant, and neuroprotective properties in a single molecule for the treatment of PD and AD [13–16]. For this purpose, to design a novel class of compounds with a multimodal mechanism of action, we selected the hydroxyquinoline (HQ) scaffold as a privileged structure since it is a clinically relevant bioactive metal chelator. Recently, 8-hydroxyquinoline (8-HQ, 1) derivatives have found application in PD and AD drug discovery [17] since 8-HQ: 1) is able to cross the blood–brain barrier (BBB) [18]; 2) is a strong iron chelator with antioxidant property [19–21]; and 3) is able to protect against the precipitation of $\beta$-amyloid plaques in presence of Cu$^{2+}$, Fe$^{3+}$, Zn$^{2+}$—compared to clioquinol—due to its ability to chelate these metals [22].
The aim of this work was to combine the antioxidant and neuroprotective properties of (R)-alpha-lipoic acid (LA, 3) and the chelant activities of 8-HQ (1) [23] to obtain a novel multi-target ligand, LA-HQ-LA (5) with multifunctional neuroprotective profile. LA-HQ-LA was obtained by linking via two ester bonds the 8-HQ derivative (5-hydroxymethyl-8-hydroxyquinoline, 2) to LA, thus increasing the lipophilicity of this molecule. LA-HQ-LA can cross plasma membranes and release HQ and two molecules of LA, thus triggering a significant decrease in oxidative stress from human SH-SY5Y neuroblastoma cells. In addition, due to the different chemical nature of the ester bonds, the derivative 5 could gradually provide a continuative and time-controlled release of LA—an elevator of GSH levels that are lower in some cerebral areas of patients affected by neurodegenerative diseases [24]—and HQ directly to specific groups of neurons characterized by cellular stress and metals accumulation.

2. Results and Discussion

Starting from 8-HQ (1), the required starting material 5-hydroxymethyl-8-hydroxyquinoline (2) was obtained in good yield, using a known procedure [25]. The new multi-target ligand LA-HQ-LA (5) was synthesized by direct condensation of 5-hydroxymethyl-8-hydroxyquinoline (2) and LA-NHS (4), previously prepared as reported by Nefkens et al. [26] (Scheme 1). The chemical structure of LA-HQ-LA was confirmed by $^1$H-, $^{13}$C-NMR, IR, and MS spectra data.

Scheme 1. Synthesis of LA-HQ-LA (5).

The neuroprotective and antioxidant capacities of LA-HQ-LA against oxidative stress were assayed by using the human SH-SY5Y neuroblastoma cell line, which is a reliable model for studying the neurotoxic effect of agents such as H$_2$O$_2$, 6-OHDA, and frequently used for elucidating the mechanisms of neurodegenerative diseases [27].

First of all, to define the suitable concentration range, the effects on cell proliferation of LA, HQ, and LA-HQ-LA were determined by colorimetric MTT assay (Figure 1). Thus, we performed dose-response experiments (with compound concentrations of 1, 10, and 100 µM) to verify if, 24 h after the treatment, the compounds added to the cells had any effect on the cell proliferative capacity. The compound concentrations of 1 and 10 µM did not show significant differences compared to the control, while at 100 µM, an antiproliferative activity was observed (Figures 1–2). In particular, at 100 µM, LA still retained a proliferative activity, while LA-HQ-LA resulted in an antiproliferative activity,
since there are no visible proliferating cells (Figure 2). Based on the results obtained, the utilized compound concentration in all the experiments reported in this study was 1 µM.

**Figure 1.** Dose-response effects of LA, HQ, and LA-HQ-LA in undifferentiated SH-SY5Y human neuroblastoma cells.

*MMTT reduction assay in undifferentiated SH-SY5Y human neuroblastoma cells in the presence of LA, HQ, and LA-HQ-LA. The cells were incubated for 24 h with increasing concentrations (1, 10, and 100 µM) of the compounds. After this period, cell viability was quantified by measuring MTT reduction. CTRL−: negative control w/o toxic. The means ± SEM derived from 3 different experiments (each with n=16; *** p < 0.0001, ** 0.0001 < p < 0.001, * 0.001 < p < 0.05, n.s. p > 0.05). * refers to SH-SY5Y human neuroblastoma cells treated only with the neuroprotective compound.*

**Figure 2.** Morphological analysis of undifferentiated SH-SY5Y human neuroblastoma cells in the presence of LA, HQ, and LA-HQ-LA.

*Morphological analysis by phase-contrast microscopy of undifferentiated SH-SY5Y human neuroblastoma cells. The cells were incubated with LA, HQ, and LA-HQ-LA (100 µM) for 24 h. The arrows indicate the cell in proliferation. (Magnification 40X)*

Because the sensitivity of cells to toxic agents may be dependent on the state of their neuronal differentiation, we used undifferentiated and RA-differentiated SH-SY5Y cells to study the neuroprotective effect of our compounds following H2O2 insult [28-29]. Thus, undifferentiated SH-SY5Y cells were pre-treated with LA, HQ, and LA-HQ-LA for 24 h and then exposed to H2O2 (25-150-300 µM) for other 24 h (cell viability was detected using MTT assay as shown in Figure 3).
Both compounds (LA-HQ-LA and LA) showed a significant protective effect against H$_2$O$_2$ at 25 and 150 µM H$_2$O$_2$. Moreover, the neuroprotective effect of LA-HQ-LA was appreciably higher in respect to LA and the control at 300 µM. In Figure 3, we did not insert the results obtained for HQ since, as evidenced by the morphological evaluation (Figure 4), at 1 µM and in presence of 25 µM of H$_2$O$_2$ it was demonstrated as toxic for the undifferentiated SH-SY5Y cells. This deleterious effect on SH-SY5Y cells could be due to a synergic action between HQ and H$_2$O$_2$. HQ, being a metal chelator of iron, copper, and zinc (transition metals that react easily with ROS), avoids the Haber-Weiss reaction between the metal and the superoxide anion; in these oxidative stress conditions, superoxide anion is overproduced, thereby damaging cells. On the other hand, H$_2$O$_2$ directly produces a high quantity of ROS further damaging the cells. These two combined actions determine a deleterious synergic effect on cells.

**Figure 3.** Neuroprotective effects of LA and LA-HQ-LA in undifferentiated and H$_2$O$_2$-lesioned SH-SY5Y human neuroblastoma cells.$^a$

![MTT reduction assay in undifferentiated and H$_2$O$_2$-lesioned SH-SY5Y human neuroblastoma cells in the presence of LA and LA-HQ-LA. The cells were incubated with the compounds (1 µM) 24 h before and during a 24-h incubation period with increasing concentrations (25, 150, or 300 µM) of H$_2$O$_2$. After this period, cell viability was quantified by measuring MTT reduction. CTRL: control with H$_2$O$_2$. The means ± SEM derived from 3 different experiments (each with n=16; ### p < 0.0001, ## 0.0001 < p < 0.001, # 0.001 < p < 0.05, n.s. p > 0.05). # is refers to SH-SY5Y human neuroblastoma cells treated with a combination of neuroprotective compound and the toxin.](image)

Many evidences indicated that the neuronal differentiation of SH-SY5Y neuroblastoma cells seems appropriate for studying neurotoxicity since the proliferation rate is limited and cells morphologically resemble the neuronal phenotype [30]. Thus, we differentiated our cells with RA to increase the cholinergic properties of SH-SY5Y cell line and we lesioned them with increasing concentrations (25–150–300 µM) of H$_2$O$_2$ (Figure 5). Results confirmed a significant neuroprotective effect of LA-HQ-LA, at all doses of H$_2$O$_2$, against LA and control. These results confirmed several previous reports [28, 31–32] which showed that the differentiation of SH-SY5Y cells by RA enhanced their resistance to the action of neurotoxic agents. In fact, comparing Figures 3 and 5, indicating cellular viability, we observed that at high concentrations of H$_2$O$_2$ (300 µM), the optical density O.D. values were reduced more in the undifferentiated than differentiated SH-SY5Y cells. Thus, the undifferentiated cells were much more vulnerable to H$_2$O$_2$ than RA-treated ones.
Figure 4. Morphological analysis of undifferentiated and H_2O_2-lesioned SH-SY5Y human neuroblastoma cells in the presence of LA, LA-HQ-LA, and HQ.\textsuperscript{a}

\textsuperscript{a} Morphological analysis by phase-contrast microscopy of undifferentiated and H_2O_2-lesioned SH-SY5Y human neuroblastoma cells. The cells were incubated with LA, LA-HQ-LA, and HQ (1 \( \mu \)M) 24 h before and during a 24-h incubation period with 25 \( \mu \)M of H_2O_2. CTRL\textsuperscript{−}: negative control w/o H_2O_2. (Magnification 40X)

Figure 5. Neuroprotective effects of LA and LA-HQ-LA in RA-differentiated and H_2O_2-lesioned SH-SY5Y human neuroblastoma cells.\textsuperscript{a}

\textsuperscript{a} MTT reduction assay in RA-differentiated and H_2O_2-lesioned SH-SY5Y human neuroblastoma cells in the presence of LA and LA-HQ-LA. The cells were incubated with the compounds (1 \( \mu \)M) 24 h before and during a 24-h incubation period with increasing concentrations (25, 150, or 300 \( \mu \)M) of H_2O_2. After this period, cell viability was quantified by measuring MTT reduction. CTRL: control with H_2O_2. The means \( \pm \) SEM derived from 3 different experiments (each with \( n = 16 \); ### \( p < 0.0001 \), ## 0.0001 < \( p < 0.001 \), # 0.001 < \( p < 0.05 \), n.s. \( p > 0.05 \)). \# is refers to SH-SY5Y human neuroblastoma cells treated with a combination of neuroprotective compound and the toxin.
Figure 6. Antioxidant capabilities of LA and LA-HQ-LA in RA-differentiated and H$_2$O$_2$-lesioned SH-SY5Y human neuroblastoma cells 

Quantitative analyses of ROS expression. ROS measurement by H$_2$DCF-DA fluorescence in RA-differentiated SH-SY5Y human neuroblastoma cells exposed to LA-HQ-LA or LA 24 h before and during a 5-minute incubation period with increasing concentrations (25, 150, or 300 μM) of H$_2$O$_2$. In this figure the fluorescence at three points (t$_0$, t$_3$, and t$_5$) during the time-course are reported. CTRL: control with H$_2$O$_2$. The means ± SEM derived from two different experiments (each with n=10; ### or *** p < 0.0001, ## or ** 0.0001 < p < 0.001, # or * 0.001 < p < 0.05, n.s. p > 0.05). * refers to SH-SY5Y human neuroblastoma cells treated only with the neuroprotective compound. # refers to SH-SY5Y human neuroblastoma cells treated with a combination of the neuroprotective compound and the toxin.

In the above reported experiments, exposing SH-SY5Y neuroblastoma cells to increasing concentrations of H$_2$O$_2$, we induced reactive oxygen species (ROS) generation. An overproduction of
ROS and a lower antioxidant capability of the cells result in oxidative stress that characterizes several neurodegenerative pathologies. To accurately measure ROS and the cell capability to counteract this insult, we used cell permeable fluorescent and chemiluminescent probes. 2′,7′-Dichlorodihydrofluorescein diacetate (H$_2$DCF-DA) is one of the most widely used techniques for directly measuring the redox state of a cell [33]. Our results showed that, at t₀-t₅ and at all the concentrations of H$_2$O$_2$, LA-HQ-LA and LA exerted a powerful antioxidant effect returning ROS levels similar to the control (Fig. 6). These data confirmed that our compound possesses good antioxidant and neuroprotective capabilities.

Comparing Figures 3, 5, and 6 we can observe that LA-HQ-LA showed a long-lasting neuroprotective activity respect to LA only in long-term experiments (Fig. 3, 5) probably due to a time-controlled release of its components.

**Figure 7.** Neuroprotective effects of LA, HQ, and LA-HQ-LA in undifferentiated and 6-OHDA-lesioned SH-SY5Y human neuroblastoma cells.

---

**Figure 7.** Neuroprotective effects of LA, HQ, and LA-HQ-LA in undifferentiated and 6-OHDA-lesioned SH-SY5Y human neuroblastoma cells.

---

* MTT reduction assay in undifferentiated and 6-OHDA-lesioned SH-SY5Y human neuroblastoma cells in the presence of LA, HQ, and LA-HQ-LA. The cells were incubated with the compounds (1 μM) 1 h before and during a 24 h incubation period with increasing concentrations (25, 50, 75, and 150 μM) of 6-OHDA. After this period, cell viability was quantified by measuring MTT reduction. CTRL: control with 6-OHDA. The means ± SEM derived from 3 different experiments (each with n=16; ### p < 0.0001, ## 0.0001 < p < 0.001, # 0.001 < p < 0.05, n.s. p > 0.05). # refers to SH-SY5Y human neuroblastoma cells treated with a combination of the neuroprotective compound and the toxin.
To further investigate the neuroprotective role in PD, it was necessary to differentiate SH-SY5Y neuroblastoma cells toward the DAergic phenotype using RA/PMA [34, 35]. We used the neurotoxin 6-OHDA as a toxic agent to lesionate the cells, as it is commonly used as a dopaminergic degeneration model for both in vitro and in vivo studies [36]. Like DA, 6-OHDA is quickly oxidized to form a variety of free radical species, and also induces ROS-dependent apoptosis in dopaminergic cells. In this second toxicity model, the neuroprotective effect of LA, HQ, and LA-HQ-LA against oxidative stress was evaluated by using the neurotoxin 6-OHDA in both the undifferentiated and RA/PMA-differentiated cells. The undifferentiated SH-SY5Y cells were treated with LA, HQ, and LA-HQ-LA for 1 h and then exposed to increasing concentrations of 6-OHDA (25-50-75-150 μM). After further 24 h of incubation, the cultures were assessed for viability by MTT assay (Figure 7). LA-HQ-LA was the most neuroprotective compound, among the ones investigated, mostly at the strongly neurotoxic 6-OHDA concentration of 150 μM. In RA/PMA-differentiated cells (Figure 8), LA-HQ-LA showed a strong neuroprotective effect at all the used concentrations of 6-OHDA. Also in these experiments, we observed a major susceptibility to toxic insult of undifferentiated respect to differentiated cells (Figures 7–8).

Figure 8. Neuroprotective effect of LA, HQ, and LA-HQ-LA in RA/PMA-differentiated and 6-OHDA-lesioned SH-SY5Y human neuroblastoma cells.ª

ª MTT reduction assay in RA/PMA-differentiated and 6-OHDA-lesioned SH-SY5Y human neuroblastoma cells in the presence of LA, HQ, and LA-HQ-LA. The cells were incubated with the compounds (1 μM) 1 h before and during a 24 h incubation period with increasing concentrations (25, 50, 75, and 150 μM) of 6-OHDA. After this period, cell viability was quantified by measuring MTT reduction. CTRL: control with 6-OHDA. The means ± SEM derived from 3 different experiments (each with n=16; ### p < 0.0001, ## p < 0.001, # 0.001 < p < 0.05, n.s. p > 0.05). # refers to SH-SY5Y human neuroblastoma cells treated with combination of neuroprotective compounds and the toxin.
Our data showed that LA-HQ-LA has a significant neuroprotective effect against both H_2O_2 and 6-OHDA, higher than LA and HQ, up to 150 μM. However, LA-HQ-LA showed a different behavior in the response (mainly with 6-OHDA) in differentiated cells compared to the undifferentiated ones. This difference probably depends on the variable sensitivity of cells against neurotoxic agents. In fact, RA/PMA-differentiated cells exhibit 6-fold higher levels of dopamine D_2 and D_3 receptors in respect to undifferentiated or RA-differentiated cells [37]. Furthermore, it is also reasonable that LA-HQ-LA showed the greatest effect against neurotoxic agents, because LA itself is a neuroprotective agent for dopaminergic neurons [38]. The obtained results confirm that LA-HQ-LA is a valid molecule, potentially more effective in respect to LA and HQ. In particular, LA-HQ-LA—at low concentrations (1 μM)—might be a good therapeutic choice in diseases such as PD, where oxidative stress caused by oxidants plays a key role.

3. Experimental Section

3.1. Chemistry

HQ (1) and LA (3) were purchased from Sigma Chemical Co. (St Louis MO, USA). All other chemicals used were of the highest commercially available purity. Chromatographic purifications were performed on silica gel using column chromatography (Merck 60, 70–230 mesh ASTM silica gel), and compounds were detected with UV light (λ = 254 nm). Optical rotations were taken at 20 °C with a Perkin-Elmer 241 polarimeter (Santa Clara, CA, USA). IR spectra were recorded with a Varian 1000 FT-IR spectrometer. NMR spectra were recorded with a Varian VXR-300 spectrometer (Varian Medical Systems, Inc., Palo Alto, CA, USA). Chemical shifts are reported in parts per million (δ) downfield from the internal standard tetramethysilane (Me_4Si). Mass spectra were obtained by electrospray ionization (ESI) in positive mode using a LCQ (Thermo Finnigan) ion trap mass spectrometer (San Jose, CA, USA) equipped with an electrospray ionization (ESI) source. The capillary temperature was set at 300 °C and the spray voltage at 4.25 kV. The fluid was nebulized using nitrogen (N_2) as both the sheath gas and the auxiliary gas.

The identity of LA-HQ-LA was confirmed by NMR, IR, and MS spectra; the homogeneity was confirmed by TLC on silica gel Merck 60 F254. Before performing biological studies, the purity of LA-HQ-LA was checked by HPLC analysis; it was determined by analytical HPLC using a Waters 600 HPLC (Waters Co., Milford, MA, USA) equipped with an X-Bridge BEH130 C-18, 5 μm, 4.6 × 250 mm column with Waters 2996 PDA detector, and an isocratic elution using water (0.1% TFA) at flow rate of 1 mL/min. LA-HQ-LA was obtained with purity greater than 98%, determined by analytical HPLC at 280 nm.

3.1.1. Synthesis of 5-Hydroxymethyl-8-hydroxyquinoline (2)

A mixture of 1 (2 g, 13.77 mmol), concentrated hydrochloric acid (4.4 mL), and 37% formaldehyde (2.2 mL) was treated with hydrogen chloride gas and stirred overnight. The reaction mixture was filtered and the precipitate was dried giving the 5-hydroxymethyl-8-hydroxyquinoline hydrochloride as a yellow solid (yield: 93%). The product was then solubilized with water and added with NaHCO_3 (3.9 g, 46.48 mmol); the precipitate was dissolved and extracted with CHCl_3/NaCl, dried over Na_2SO_4, and
the solvent was removed under vacuum obtaining 2 as a white solid (yield: 68%). $^1$H-NMR (300 MHz, DMSO-d$_6$) $\delta$: 4.78–4.83 (2H, m, CH$_2$, HQ), 5.16 (1H, s, OH, HQ), 6.96–7.57 (3H, m, Ar, HQ), 8.47–8.83 (2H, m, Ar, HQ), 9.70 (1H, s, br, OH); $^{13}$C-NMR (300 MHz, DMSO-d$_6$): 111.35–153.07 (9 × CH, HQ).

3.1.2. Synthesis of 1-([5-[1,2]dithiolan-3-yl-pentanoyl]-pyrrolidine-2,5-dione (LA-NHS, 4)

A solution of 3 (3.69 g, 19.2 mmol) in dry dioxane (15.4 mL) was slowly added to a mixture of NHS (2.3 g, 20 mmol) and DCC (4.12 g, 20 mmol) in dry dioxane (37 mL) and stirred for 48 h at room temperature. After filtration of the precipitate, the solvent was evaporated, the residue was taken up in 2-propanol, and left over night at 4 °C. The resulting white precipitate 4 was then filtered and dried (yield: 60%). $^1$H-NMR (300 MHz, DMSO-d$_6$) $\delta$: 1.25 (2H, m, CH$_2$, LA), 1.37–1.62 (4H, m, 2 × CH$_2$, LA), 1.84 (2H, m, CH$_2$, LA), 2.29 (2H, t, CH$_2$, LA), 2.42–2.51 (3H, m, CH$_2$ and CH, LA), 2.78 (4H, t, 2 x CH$_2$, NHS); $^{13}$C-NMR (300 MHz, DMSO-d$_6$): 28.1 (C$_2$H$_2$, LA), 29.5 (C$_2$H$_2$, LA), 33.0 (2 x C$_2$H$_2$, NHS), 33.5 (CH$_2$, LA), 34.8 (CH$_2$, LA), 37.9 (CH$_2$, LA), 42.9 (CH$_2$, LA), 55.7 (CH, LA), 107.4 (CH, NHS), 172.3 (CO, LA), 205.2 (2 × CO, NHS).

3.1.3. Synthesis of LA-HQ-LA (5)

5-Hydroxymethyl-8-hydroxyquinoline (2) (440 mg, 2.5 mmol) was dissolved in dry CH$_2$Cl$_2$ (72 mL) and then added to a stirring mixture of 4 (3.03 g, 10 mmol) and DCC (2.06 g, 10 mmol) in dry CH$_2$Cl$_2$ (72 mL). The reaction mixture was left at room temperature for 48 h under stirring, then the solution was filtered and the solvent was removed. The obtained residue was chromatographed using petroleum ether: AcOEt (6:4) as eluant to give LA-HQ-LA as a yellow oil (yield: 57%). $R_f$ = 0.72 (petroleum ether:AcOEt (6:4)); $[\alpha]_D^{20}$ = + 20.0 (c=1 in MeOH); $^1$H-NMR (300 MHz, CDCl$_3$) $\delta$: 1.42 (2H, m, CH$_2$, LA), 1.8 (12H, m, 6 × CH$_2$, LA), 2.36 (2H, m, CH$_2$, LA), 2.47 (2H, m, CH$_2$, LA), 2.81 (2H, t, CH$_2$, LA), 3.12 (4H, m, 2 x CH$_2$, LA), 3.49 (1H, m, LA), 3.63 (1H, m, LA), 5.52 (2H, s, Ar-CH$_2$-O), 7.42 (1H, d, HQ), 7.50 (1H, m, HQ), 7.60 (1H, d, HQ), 8.38 (1H, d, HQ), 8.93 (1H, d, HQ). $^{13}$C-NMR (300 MHz, CDCl$_3$) $\delta$: 24.85 (CH$_2$, LA), 24.93 (CH$_2$, LA), 28.85 (OOCCH$_2$-C$_2$H$_2$, LA), 28.86 (OOCCH$_2$-C$_2$H$_2$, LA), 34.18 (OOC-CH$_2$, LA), 34.24 (OOC-CH$_2$, LA), 34.77 (CH$_2$, LA), 34.9 (CH$_2$, LA), 38.74 (2 x CH$_2$, LA), 40.41 (CH$_2$, LA), 40.48 (CH$_2$, LA), 56.49 (CH, LA), 56.65 (CH, LA), 63.48 (COO-CH$_2$-HQ), 121.07 (CH, HQ), 122.27 (CH, HQ), 128.25 (CH, HQ), 130.30 (C-OOC, HQ), 132.56 (CH, HQ), 148.34 (C-N, HQ), 150.56 (N-CH, HQ), 172.48 (COO, LA), 173.39 (COO, LA); IR (KBr): $\tilde{v}$ = 3409, 2932, 2283, 1733, 1461, 1376, 1259, 1182, cm$^{-1}$; MS (ESI) m/z 552.12 (M+H)$^+$.

3.2. Neuroprotective Studies

3.2.1. SH-SY5Y Cell Culture

Human SH-SY5Y neuroblastoma cells (EGACC, Sigma–Aldrich, UK) were grown at 37 °C, in a humid 5% CO$_2$, in Dulbecco’s Modified Eagle’s medium supplemented with 10% heat-inactivated fetal bovine serum, penicillin (100 U/mL), streptomycin (100 µg/mL), and 1% L-glutamine. SH-SY5Y cells were plated onto 96-well plates (2,700 cell/well). Undifferentiated cells (UN) were
grown for 24 h in normal medium and then incubated with the compounds (LA, HQ, and LA-HQ-LA). After 24 h of incubation, the cultures were assessed for viability by using a colorimetric assay based on the ability of living cells to reduce a tetracycline-based compound to a blue formazan product (MTT assay). At the end of incubation, 20 μL of MTT (5 mg/mL in PBS) were added to each well and the incubation continued for an additional 3 h at 37 °C. The plate was centrifuged at 2000 rpm for 15 min. The MTT solution was carefully decanted off and formazan crystals were dissolved with 200 μL DMSO at 37 °C for 30 min. Finally, samples were read in a TiterTek Multiscan Microeliza Reader (Flow Laboratories, Urvine, UT, USA) at 540 nm. All MTT assays were repeated nine times. The neuroprotective effects of HQ (1 μM), LA (1 μM), and LA-HQ-LA (1 μM) in undifferentiated cells were tested for 24 h in the presence of two neurotoxic agents: H₂O₂ (25-150-300 μM) and 6-OHDA (50-75-150 μM).

To obtain a cholinergic phenotype, SH-SY5Y cells were grown in a medium containing retinoic acid (RA) (10 μM) for 3 days; then the medium was removed and replaced with fresh RA (10 μM) medium for other 3 days of differentiation. Alternatively, to have a dopaminergic phenotype, the cells were treated with RA/ phorbol 12-myristate 13-acetate (PMA) in a medium supplemented of RA (10 μM) for 3 days; then the medium was removed and replaced with growth medium containing PMA (80 nM) for a subsequent 3 days. The neuroprotective effects of LA, HQ, and LA-HQ-LA at the concentration of 1 μM were evaluated on differentiated cells exposed to 6-OHDA (25-50-75-150 μM) and H₂O₂ (25-150-300 μM).

3.2.2. Measurement of Intracellular ROS

Intracellular ROS were quantified by the 2',7'-dichlorodihydrofluorescein diacetate (H₂DCF-DA) assay using a Microplate Fluorometer SPECTRAmax Gemini XS (Molecular Devices, Sunnyvale, CA, U.S.A.) at excitation and emission wavelengths of 480 nm and 530 nm, respectively, and analyzed by SOFTmax Pro software (Version 5.0; Molecular Devices). DCFH-DA is transported across the cell membrane and deacetylated by esterases to form the non-fluorescent 2',7'-dichlorofluorescein (DCFH). This compound is trapped inside the cells. Next, DCFH is converted to DCF through the action of peroxide rated by the presence of peroxidase. SH-SY5Y cells were plated (2000 cells/well) into special-optics 96-well plates (Corning-Costar). 24 hours later, the cells were washed 3 times with imaging buffer (125 mM NaCl, 5 mM KCl, 1.2 mM MgSO₄, 5 mM glucose, 25 mM Hepes, 2 mM CaCl₂). Then 10 μM DCFH-DA media solution were added and the plates were incubated at 37 °C for 30 minutes. After 2 washings with imaging buffer, cells were treated with 25, 150, or 300 μM H₂O₂ for immediate fluorescence measurement. The fluorescence intensity is proportional to the ROS levels within the cell cytosol and in inverse proportion to the antioxidant capacity of the cells themselves. Plates, maintained at 25 °C, were read for kinetic analysis in increments from 0 to 5 minutes every 30 seconds [39].

Statistical analysis. The statistical analysis (unpaired t test) was performed with GraphPad Prism 5 software version 5.0. One-way ANOVA was computed for each level of treatment followed by Dunnett’s t-test post hoc.
4. Conclusions

In conclusion, we synthesized a novel multi-target ligand—containing antioxidant and chelant groups—that might represent a step forward in the search for new molecules against neurodegenerative diseases. LA-HQ-LA was superior to the single molecules (LA and HQ), for the antioxidant and neuroprotective activities against 6-OHDA and H$_2$O$_2$. Particularly, it displayed a strong neuroprotective effect against all the used concentrations of 6-OHDA, reporting the values similar to those of the control. Clearly, proof of the concept will involve an investigation of its in vivo neuroprotective profile.

Although much needs to be understood in terms of pathogenesis of neurodegeneration, it is clear that the simultaneous modulation of oxidative stress and metal brain levels can be considered as a potential strategy to interrupt the vicious cycle that accelerates the progression of the neurodegenerative diseases, such as PD and AD.

Acknowledgments

Financial support from Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR) is gratefully acknowledged.

Conflict of Interest

The authors declare no conflict of interest.

References

1. Mark, P.M. Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders. *Ann. N.Y. Acad. Sci.* 2004, 1012, 37–50.
2. Jellinger, K.A. General aspects of neurodegeneration. *J. Neural Transm. Suppl.* 2003, 65, 101–144.
3. Lepoivre, M.; Flaman, J.M.; Bobè, P.; Lemaire, G.; Henry, Y. Quenching of the tyrosyl free radical of ribonucleotide reductase by nitric oxide. *J. Bio. Chem.* 1994, 269, 21891–21897.
4. Bush, A.I. Metals and neuroscience. *Curr. Opin. Chem. Biol.* 2000, 4, 184–191.
5. Crichton, R.R.; Dexter, D.T.; Ward, R.J. Metal based neurodegenerative diseases - From molecular mechanism to therapeutic strategies. *Coordin. Chem. Rev.* 2008, 252, 1189–1199.
6. Schulz, J.B.; Lindenau, J.; Seyfried, J. Dichganz, J. Glutathione, oxidative stress and neurodegeneration. *Eur. J. Biochem.* 2000, 267, 4904–4911.
7. Cuajungco, M.P.; Faget, K.Y.; Huang, X.; Tanzi, R.E.; Bush, A.I. Metal chelation as a potential therapy for Alzheimer’s disease. *Ann. N.Y. Acad. Sci.* 2000, 920, 292–304.
8. Sozio, P.; Iannitelli, A.; Cerasa, L.S.; Cacciatore, I; Cornacchia, C.; Giorgioni, G.; Ricciutelli, M.; Nasuti, C.; Cantalamessa, F.; Di Stefano, A. New L-Dopa codrugs as potential antiparkinson agents. *Arch. Pharm.* 2008, 341, 412–417.
9. Cacciatore, I.; Cornacchia, C.; Pinnen, F.; Mollica, A.; Di Stefano, A. Prodrug approach for increasing cellular glutathione levels. *Molecules* 2010, 15, 1242–1264.
10. Cornacchia, C.; Cacciatore, I.; Baldassarre, L.; Mollica, A.; Feliciani, F.; Pinnen, F. Diketopiperazines as neuroprotective agents. *Mini-Rev. Med. Chem.* 2012, 12, 2–12.
11. Pinnen, F.; Cacciatore, I.; Cornacchia, C.; Mollica, A.; Sozio, P.; Cerasa, L.S.; Iannitelli, A.; Fontana, A.; Nasuti, C.; Di Stefano, A. CNS delivery of L-dopa by a new hybrid glutathione-methionine peptidomimetic prodrug. *Amino Acids* 2012, 42, 261–269.

12. Minelli, A.; Conte, C.; Grottelli, S.; Bellezza, I.; Cacciatore, I.; Bolaños, J. Cyclo(His-Pro) promotes cytoprotection by activating Nrf2-mediated up-regulation of antioxidant defence. *J. Cell. Mol. Med.* 2009, 13, 1149–1161.

13. Minelli, A.; Conte, C.; Prudenzi, E.; Cacciatore, I.; Cornacchia, C.; Taha, E.; Pinnen, F. N-acetyl-L-methionyl-L-Dopa-methyl ester as a dual acting drug that relives L-Dopa-induced oxidative toxicity. *Free Radical Bio. Med.* 2010, 49, 31–39.

14. Minelli, A.; Conte, C.; Cacciatore, I.; Cornacchia, C.; Pinnen, F. Molecular mechanism underlying the cerebral effect of Gly-Pro-Glu tripeptide bound to L-Dopa in a Parkinson's animal model. *Amino Acids* 2012, 43, 1359–1367.

15. Cacciatore, I.; Cornacchia, C.; Baldassarre, L.; Fornasari, E.; Mollica, A.; Stefanucci, A.; Pinnen, F. GPE and GPE analogues as promising neuroprotective agents. *Mini-Rev. Med. Chem.* 2012, 12, 13–23.

16. Pinnen, F.; Sozio, P.; Cacciatore, I.; Cornacchia, C.; Mollica, A.; Iannitelli, A.; D’Aurizio, E.; Cataldi, A.; Zara, S.; Nasuti, C.; Di Stefano, A. Ibuprofen and glutathione conjugate as a potential therapeutic agent for treating Alzheimer's disease. *Arch. Pharm.* 2011, 344, 139–148.

17. Bongarzone, S.; Bolognesi, M.L. The concept of privileged structures in rational drug design: Focus on acridine and quinoline scaffolds in neurodegenerative and protozoan diseases. *Expert Opin. Drug Dis.* 2011, 6, 251–268.

18. Frederickson, C.J.; Kasarskis, E.J.; Ringo, D.; Frederickson, R.E. A quinoline fluorescence method for visualizing and assaying the histochimically and reactive zinc (bouton zinc) in the brain. *J. Neurosci. Methods* 1987, 20, 91–103.

19. Turnquist, T.D.; Sandell, E.B. Stability constants of iron (III)-8-hydroxyquinoline complexes. *Anal. Chim. Acta* 1968, 42, 239–245.

20. Kayyali, R.; Pannala, A.S.; Khodr, H.; Hider, R.C. Comparative radical scavenging ability of bidentate iron (III) chelators. *Biochem. Pharmacol.* 1998, 55, 1327–1332.

21. Ben-Shachar; D.; Kahana; N.; Kampel; V.; Warshawsky, A.; Youdim, M.B. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. *Neuropharmacology* 2004, 46, 254–263.

22. Dickens, M.G.; Franz, K.J. A Prochelator activated by hydrogen peroxide prevents metal-induced amyloid beta aggregation. *Chem. Bio. Chem.* 2010, 11, 59–62.

23. Di Vaira, M.; Bazzicalupi, C.; Orioli, P.; Messori, L.; Bruni, B.; Zatta, P. Clioquinol, a drug for Alzheimer’s disease specifically interfering with brain metal metabolism: structural characterization of its zinc(II) and copper(II) complexes. *Inorg. Chem.* 2004, 43, 3795–3797.

24. Cacciatore, I.; Baldassarre, L.; Fornasari, E.; Mollica, A.; Pinnen, F. Recent advances in the treatment of neurodegenerative diseases based on GSH delivery systems. *Oxid. Med. Cell. Longev.* 2012, 240146.

25. Li, L.; Xu, B. Synthesis and characterization of 5-substituted 8-hydroxyquinoline derivatives and their metal complexes. *Tetrahedron* 2008, 64, 10986–10995.
26. Nefkens, G.H. L.; Tesser, G.I. A novel activated ester in peptide syntheses. *J. Am. Chem. Soc.* 1961, 83, 1263–1263.

27. Xie, H.; Hu, L.; Li, G. SH-SY5Y human neuroblastoma cells line: in vitro cell model of dopaminergic neurons in Parkinson’s disease. *Chin. Med. J.* 2010, 123, 1086–1092.

28. Lombet, A.; Zujovic, V.; Kandouz, M.; Billardon, C.; Carvajal-Gonzalez, S.; Gompel, A.; Rostène, W. Resistance to induced apoptosis in the human neuroblastoma cell line SK-N-SH in relation to neuronal differentiation: Role of Bcl-2 protein family. *Eur. J. Biochem.* 2001, 268, 1352–1362.

29. Ho, R.; Minturn, J.E.; Hishiki, T.; Zhao, H.; Wang, Q.; Cnaan, A.; Maris, J.; Evans, A.E.; Brodeur, G.M. Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. *Cancer Res.* 2005, 65, 9868–9875.

30. Jantas, D.; Pytel, M.; Mozrzymas, J.W.; Leskiewicz, M.; Regulska, M.; Antkiewicz-Michaluk, L.; Lason, W. The attenuating effect of memantine on staurosporine-, salsolinol- and doxorubicin-induced apoptosis in human neuroblastoma SH-SY5Y cells. *Neurochem. Int.* 2008, 52, 864–877.

31. Middlemas, D.S.; Kihl, B.K.; Moody, N.M. Brain derived neurotrophic factor protects human neuroblastoma cells from DNA damaging agents. *J. Neuro-Oncol.* 1999, 45, 27–36.

32. Tieu, K.; Zuo, D.M.; Yu, P.H. Differential effects of staurosporine and retinoic acid on the vulnerability of the SH-SY5Y neuroblastoma cells: Involvement of Bcl-2 and p53 proteins. *J. Neurosci. Res.* 1999, 58, 426–435.

33. LeBel, C.P.; Ischiropoulos, H.; Bondy, S.C. Evaluation of the probe 2′,7′-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. *Chem. Res. Toxicol.* 1992, 5, 227–231.

34. Lopes, F.M.; Londero, G.F.; de Medeiros, L.M.; da Motta, L.L.; Behr, G.A.; de Oliveira, V.A.; Ibrahim, M.; Moreira, J.C.; de Oliveira Porciúncula, L.; da Rocha, J.B.; Klamt, F. Evaluation of the neurotoxic/neuroprotective role of organoselenides using differentiated human neuroblastoma SH-SY5Y cell line challenged with 6-hydroxydopamine. *Neurotox Res.*, 2012; 22, 138–149.

35. Lopes, F.M.; Schröder, R.; da Frota, M.L.; Zanotto-Filho, A.; Müller, C.B.; Pires, A.S.; Meurer, R.T.; Colpo, G.D.; Gelain, D.P.; Kapczinski, F.; Moreira, J.C.; Fernandes Mda, C.; Klamt, F. Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies. *Brain Res.* 2010, 1337, 85–94.

36. Lehmensiek, V.; Tan, E.M.; Liebau, S.; Lenk, T.; Zettlmeisl, H.; Schwarz, J.; Storch, A. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant α-synucleins related to Parkinson's disease. *Neurochem. Int.* 2006, 48, 329–340.

37. Presgraves, S.P.; Ahmed, T.; Borwege, S.; Joyce, J.N. Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists. *Neurotox. Res.* 2003, 5, 579–598.

38. Cacciatore, I.; Baldassarre, L.; Fornasari, E.; Cornacchia, C.; Di Stefano, A.; Sozio, P.; Cerasa, L.S.; Fontana, A.; Fulle, S.; Di Filippo, E.S.; La Rovere, R.M.; Pinnen, F. (R)-alpha-Lipoyl-glycyl-L-prolyl-L-glutamyl dimethyl ester codrug as multifunctional agent with potential neuroprotective activities. *Chem. Med. Chem.* 2012, 7, 2021–2029.
39. Menghini, L.; Leporini, L.; Scanu, N.; Pintore, G.; La Rovere, R.; Di Filippo, E.S.; Pietrangelo, T.; Fulle, S. Effect of phytochemicals concentrations on biological activities of cranberry extracts. *J. Biol. Reg. Homeos. Ag.* **2011**, *25*, 27–35.

© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).